M12

M12 is Microsoft’s venture arm, investing across enterprise software, AI infrastructure, security, and selectively in health technology where the company integrates with the broader Microsoft cloud and AI stack. Stage focus runs from Series A through later venture rounds, with checks typically in the $2M to $10M range and the capacity to participate in significantly larger syndicates. Healthcare exposure is opportunistic rather than dedicated and tends toward enterprise health software, AI applied to clinical or administrative workflows, and infrastructure that benefits from Azure adoption. Physician founders building enterprise health AI on Azure, clinical NLP, or population health software with clear commercial pull are the right profile. Founders building therapeutics, hardware-heavy devices, or consumer health brands are out of scope. Geographic posture is global, with deal capacity in North America, Europe, and Israel. The realistic entry path is warm introduction from a Microsoft business unit owner, a co-investing fund, or an existing portfolio CEO; M12 partners value strategic alignment and will involve relevant Microsoft product leaders during diligence, which can extend timelines but adds significant commercial leverage. Founders should arrive with a clear Azure or M365 integration narrative, defended unit economics, and a willingness to engage strategically without being captured. Treat M12 as a serious co-investor that brings cloud distribution, technical credibility, and selective leadership, more than a category lead in healthcare specifically.